Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.
|Articles|February 1, 2003
Ms.Codit
Author(s)Inga Ellzey
Q: My doctors commonly use the following example in their dictation: "IDN back, no other suspicious lesions noted on complete general cutaneous skin exam." Would this documentation support a 99213, 99202, or 99242 level of care since six body areas are required to meet the documentation guidelines for the examination?
Advertisement
Advertisement
Related to this article
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.
This review of the latest dermatological studies includes insights on
Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
Maui Derm NP+PA Fall 2026 brought APPs together for updates spanning inflammatory disease, oncology, emerging therapies, and diagnostic challenges.
Advertisement
Advertisement
Trending on Dermatology Times
1
IMVT-1402 Misses Primary Endpoint in Cutaneous Lupus Proof-of-Concept Trial
2
ORKA-001 Achieves Deepening Skin Clearance Through Week 28 in Plaque Psoriasis
3
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
4
FDA Grants Fast Track Designation to QRX003 for Peeling Skin Syndrome
5